Preclinical CRO Market Size To Reach USD 11.18 BN By 2032

The global preclinical CRO market size reached USD 5.78 billion in 2023 and is projected to hit USD 11.18 billion by 2032 with a CAGR of 7.60% from 2023 to 2032.

Key Takeaway:

The bioanalysis and DMPK studies segment is poised to register a growth at a CAGR of 8.5% from 2023 to 2032.
The government and academic institutes segment is expected to grow at a CAGR of 8.2% from 2023 to 2032.
Asia Pacific region is expected to grow at a CAGR of 10.9% Over the forecast period 2023 to 2032.

The global preclinical CRO market is primarily driven by the rapid growth of the pharmaceutical and the medical devices companies. The rising burden of numerous chronic diseases along with the increasing need for their diagnosis, prevention, and treatment related drugs and devices is significantly driving the market. The various biopharmaceutical companies and academic institutions areincreasingly investing and outsourcing the preclinical studies activities to the CROs owing to the increasing need for the development of new and innovative medicines. The favorable government policies regarding the development of preclinical studies of various diseases and its cure are driving the demand for the preclinical CRO services across the globe.

Get Report Sample Copy @ https://www.precedenceresearch.com/sample/1361

The recent outbreak of the COVID-19 pandemic compelled the pharmaceutical industry players and research institutions to infuse investments in the CROs to conduct the research activities regarding the COVID-19 virus. Therefore, rising investments in the preclinical CROs by various stakeholders is expected to drive the growth of the global preclinical CRO market.

The rapidly growing number of biopharmaceutical companies across the globe, especially in the developed and developing regions is deriving the demand for the preclinical CRO services. Mostly, the small and the medium sized biopharmaceutical enterprises has low resources and expertise to conduct preclinical studies and hence, they are increasingly outsourcing this tasks to the preclinical CROs, which in turn, boosts the growth of the preclinical CRO market across the globe. In this way the rising number of biopharmaceutical companies are positively impacting the market.

The rising burden of diseases is boosting the demand for various medical devices and diagnosis equipment that can provide fast and accurate results and re non-invasive. Therefore, rising investments by the medical device companies in the preclinical CRO services is another major factors that plays an exceptional role in the growth and development of the preclinical CRO market.

Table of Contents

Report Scope of the Preclinical CRO Market

Report Highlights	Details
Market Size	USD 11.18 Billion by 2032
Growth Rate	CAGR of 7.60% From 2023 to 2032
Largest Market	North America
Fastest Growing Market	Asia Pacific
Base Year	2022
Forecast Period	2023 to 2032
Segments Covered	Service, End User, Region

North America is the dominating preclinical CRO market that accounted for a market share of over 45% in 2020. The North America is characterized by the rapid growth of the CROs and biopharmaceutical companies. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), US conducts more than half of the research & development activities in the pharmaceutical field and also holds intellectual rights of a significant amount of new medicines. The biopharmaceutical industry accounted for around 4% of the US GDP in 2015. Moreover, higher adoption rate of advanced technologies along with the adequate amount of funding is boosting the entire ecosystem of preclinical studies and drug development process in US.

Asia Pacific is well known for the presence of few top CROs in the regions like China, India, and South Korea. The favorable government policies to attract FDIs and rising government expenditure of building sophisticated healthcare infrastructure is favoring the growth of the preclinical CRO market in Asia Pacific. Moreover, the cost-efficiency of the CROs in this region is expected to drive the growth of the market during the forecast period.

Lack of adequate investments in the underdeveloped economies to develop and expand the preclinical CRO industry is anticipated to be a major challenge to the industry and this may hamper the market growth in the forthcoming years. Moreover, there is a lack of standardization as the CROs fails to comply with certain standards such as good laboratory practices and there work quality are questionable. This factor may hamper the market growth in the upcoming future.

Based on the service, the bioanalysis & DMPK studies segment is estimated to be the fastest-growing segment during the forecast period. Bioanalysis is provides quantitative insights regarding the preclinical studies and is used at each and every step of the new drug development process. Further, the DMPK facilitates the toxicology testing, which itself is a very large segment and hence the DMPK is expected to grow rapidly during the forecast period.

Based on the end use, the biopharmaceutical segment dominated the market, garnering a market share of around 80% in 2020. The rising government initiatives to fund and develop the biopharmaceutical industry resulted in a surging growth of this segment. Biopharmaceutical industry represents around 20% of the global pharmaceutical market and is expected to rise further in the foreseeable future, which in turn is expected to drive the demand for the preclinical CRO services.